CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2017-2021

被引:0
|
作者
Price, Mackenzie [1 ]
Ballard, Christine [1 ,2 ]
Benedetti, Julia [1 ,2 ]
Neff, Corey [1 ,2 ]
Cioffi, Gino [1 ,3 ]
Waite, Kristin A. [1 ,3 ]
Kruchko, Carol [1 ]
Barnholtz-Sloan, Jill S. [1 ,3 ,4 ]
Ostrom, Quinn T. [1 ,2 ,5 ,6 ]
机构
[1] Cent Brain Tumor Registry US, Hinsdale, IL USA
[2] Duke Univ, Sch Med, Dept Neurosurg, Durham, NC 27710 USA
[3] NCI, Trans Div Res Program, Div Canc Epidemiol & Genet, NIH, Bethesda, MD USA
[4] NCI, Ctr Biomed Informat & Informat Technol, NIH, Bethesda, MD USA
[5] Duke Univ, Preston Robert Tisch Brain Tumor Ctr, Sch Med, Durham, NC 27710 USA
[6] Duke Univ, Duke Canc Inst, Med Ctr, Durham, NC 27710 USA
关键词
CANCER INCIDENCE; EPIDEMIOLOGY; CLASSIFICATION; COMPLETENESS; SURVIVAL; GLIOMA; IMPACT; RATES;
D O I
10.1093/neuonc/noae145
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The Central Brain Tumor Registry of the United States (CBTRUS), in collaboration with the Centers for Disease Control and Prevention and the National Cancer Institute, is the largest population-based registry focused exclusively on primary brain and other central nervous system (CNS) tumors in the United States (US) and represents the entire US population. This report contains the most up-to-date population-based data on primary brain tumors available and supersedes all previous reports in terms of completeness and accuracy. All rates are age-adjusted using the 2000 US standard population and presented per 100,000 population. Between 2017 and 2021, the average annual age-adjusted incidence rate (AAAIR) of all primary malignant and non-malignant brain and other CNS tumors was 25.34 per 100,000 population (malignant AAAIR=6.89 and non-malignant AAAIR=18.46). This overall rate was higher in females compared to males (28.77 versus 21.78 per 100,000) and non-Hispanic Black persons compared to persons who were non-Hispanic White (26.60 versus 25.72 per 100,000), non-Hispanic American Indian/Alaska Native (23.48 per 100,000), non-Hispanic Asian or Pacific Islander (19.86 per 100,000), and Hispanic persons of all races (22.37 per 100,000). Gliomas accounted for 22.9% of all tumors. The most commonly occurring malignant brain and other CNS histopathology was glioblastoma (13.9% of all tumors and 51.5% of all malignant tumors), and the most common predominantly non-malignant histopathology was meningioma (41.7% of all tumors and 56.8% of all non-malignant tumors). Glioblastomas were more common in males, and meningiomas were more common in females. In children and adolescents (ages 0-19 years), the incidence rate of all primary brain and other CNS tumors was 6.02 per 100,000 population. There were 87,053 deaths attributed to malignant brain and other CNS tumors between 2017 and 2021. This represents an average annual mortality rate of 4.41 per 100,000 population and an average of 17,411 deaths per year. The five-year relative survival rate following diagnosis of a malignant brain or other CNS tumor was 35.7%. For a non-malignant brain or other CNS tumor the five-year relative survival rate was 92.0%.
引用
收藏
页码:vi1 / vi85
页数:85
相关论文
共 50 条
  • [41] Complete prevalence of malignant primary brain tumors registry data in the United States compared with other common cancers, 2010
    Zhang, Adah S.
    Ostrom, Quinn T.
    Kruchko, Carol
    Rogers, Lisa
    Peereboom, David M.
    Barnholtz-Sloan, Jill S.
    NEURO-ONCOLOGY, 2017, 19 (05) : 726 - 735
  • [42] The need for a central brain tumor registry in Africa: A review of central nervous system tumors in Africa from 1960 to 2017
    Feh, Marilyn Keng-Nasang Mbi
    Lyon, Kristopher A.
    Brahmaroutu, Ankita, V
    Tadipatri, Ramya
    Fonkem, Ekokobe
    NEURO-ONCOLOGY PRACTICE, 2021, 8 (03) : 337 - 344
  • [43] Multiple primary tumors involving cancer of the brain and central nervous system as the first or subsequent cancer
    Inskip, PD
    CANCER, 2003, 98 (03) : 562 - 570
  • [44] Stereotactic radiosurgical treatment of brain metastasis of primary tumors that rarely metastasize to the central nervous system
    Menendez, Joshua Y.
    Bauer, David F.
    Shannon, Chevis N.
    Fiveash, John
    Markert, James M.
    JOURNAL OF NEURO-ONCOLOGY, 2012, 109 (03) : 513 - 519
  • [45] Primary central nervous system tumor treatment and survival in the United States, 2004-2015
    Garcia, Catherine R.
    Slone, Stacey A.
    Dolecek, Therese A.
    Huang, Bin
    Neltner, Janna H.
    Villano, John L.
    JOURNAL OF NEURO-ONCOLOGY, 2019, 144 (01) : 179 - 191
  • [46] Incidence and survival of primary central nervous system tumors diagnosed in 4 Canadian provinces from 2010 to 2015
    Walker, Emily V.
    Davis, Faith G.
    Yasmin, Farzana
    Smith, Trenton R.
    Yuan, Yan
    NEURO-ONCOLOGY PRACTICE, 2023, 10 (02) : 203 - 213
  • [47] The Prognostic Value of Tumor Markers in Newly Diagnosed Patients With Primary Central Nervous System Germ Cell Tumors
    Kim, AeRang
    Ji, Lingyun
    Balmaceda, Casilda
    Diez, Blanca
    Kellie, Stewart J.
    Dunkel, Ira J.
    Gardner, Sharon L.
    Sposto, Richard
    Finlay, Jonathan L.
    PEDIATRIC BLOOD & CANCER, 2008, 51 (06) : 768 - 773
  • [48] Incidence and spatial distribution of adult-onset primary malignant and other central nervous system tumors in Southern Sardinia, Italy
    Pierri, Vincenzo
    Dagostino, Sabino
    Vasta, Rosario
    Ercoli, Tommaso
    Piga, Giuseppe
    Melas, Valerio
    Bruder, Francesca
    Conti, Carlo
    Cappai, Pier Francesco
    Manieli, Cristina
    Melis, Maurizio
    Floris, Gianluca
    Melis, Marta
    Muroni, Antonella
    Maleci, Alberto
    Defazio, Giovanni
    NEUROLOGICAL SCIENCES, 2022, 43 (01) : 419 - 425
  • [49] Epidemiology of pediatric primary malignant central nervous system tumors in Iran: A 10 year report of National Cancer Registry
    Beygi, Sara
    Saadat, Soheil
    Jazayeri, Seyed Behzad
    Rahimi-Movaghar, Vafa
    CANCER EPIDEMIOLOGY, 2013, 37 (04) : 396 - 401
  • [50] An updated histology recode for the analysis of primary malignant and nonmalignant brain and other central nervous system tumors in the Surveillance, Epidemiology, and End Results Program
    Forjaz, Goncalo
    Barnholtz-Sloan, Jill S.
    Kruchko, Carol
    Siegel, Rebecca
    Negoita, Serban
    Ostrom, Quinn T.
    Dickie, Lois
    Ruhl, Jennifer
    Van Dyke, Alison
    Patil, Nirav
    Cioffi, Gino
    Miller, Kimberly D.
    Waite, Kristin
    Mariotto, Angela B.
    NEURO-ONCOLOGY ADVANCES, 2021, 3 (01)